Thanks Matrix and TP The most interesting point for me from that...

Thanks Matrix and TP
The most interesting point for me from that audio was Peter Hall saying that the FDA had wanted the primary end point to be overall PFS. When I asked before why the endpoint was as it was I was referred to Professor Van Cutsem's presentation last October and, while he did not to my knowledge mention the FDA, he did suggest that smaller trials had already demonstrated that the secondary endpoint was almost certain to be achieved, and I inferred from that that the more ambitious endpoint had been attempted in order to demonstrate something new. It now appears that my inference was wrong. That still leaves a puzzle as to why the company believed that improved overall PFS would be achieved in patients with cancers in other organs by the Sirtex procedure directed solely at the liver.